Abpro Bio Balance Sheet Health
Financial Health criteria checks 6/6
Abpro Bio has a total shareholder equity of ₩122.3B and total debt of ₩10.9B, which brings its debt-to-equity ratio to 8.9%. Its total assets and total liabilities are ₩142.1B and ₩19.8B respectively.
Key information
8.9%
Debt to equity ratio
₩10.88b
Debt
Interest coverage ratio | n/a |
Cash | ₩19.87b |
Equity | ₩122.34b |
Total liabilities | ₩19.77b |
Total assets | ₩142.11b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A195990's short term assets (₩44.8B) exceed its short term liabilities (₩17.9B).
Long Term Liabilities: A195990's short term assets (₩44.8B) exceed its long term liabilities (₩1.8B).
Debt to Equity History and Analysis
Debt Level: A195990 has more cash than its total debt.
Reducing Debt: A195990's debt to equity ratio has reduced from 42.3% to 8.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A195990 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A195990 has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 10.6% each year.